| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Hui Wang | |
| Yun Liu | |||
| Qiang Wu | |||
| Hu-Biao Chen | |||
| Jian-Ye Zhang | |||
| Rameshwar Adhikari | |||
| Chao-Yue Su | |||
| Yan-Yan Yan | |||
| Qiao-Ru Guo | |||
| Ying-da Yan | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| The nuclear RNase III Drosha initiates microRNA processing | Q24295234 | ||
| The DNA-damage response in human biology and disease | Q24606586 | ||
| Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200 | Q24616100 | ||
| MicroRNA-1246 is an exosomal biomarker for aggressive prostate cancer | Q50046172 | ||
| Tumour heterogeneity and resistance to cancer therapies | Q50112440 | ||
| Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. | Q51134076 | ||
| Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. | Q52594711 | ||
| Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway. | Q52660179 | ||
| Metastasis-associated miR-23a from nasopharyngeal carcinoma-derived exosomes mediates angiogenesis by repressing a novel target gene TSGA10. | Q52665687 | ||
| Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. | Q52844139 | ||
| Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization. | Q52862197 | ||
| Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). | Q53217202 | ||
| Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. | Q53689677 | ||
| Recent Advances in the Treatment of Breast Cancer. | Q55353691 | ||
| Exosome-Derived miR-130a Activates Angiogenesis in Gastric Cancer by Targeting C-MYB in Vascular Endothelial Cells | Q57039811 | ||
| Exosome-mediated cell-cell communication in tumor progression | Q57494142 | ||
| In Situ Detection of Plasma Exosomal MicroRNA-1246 for Breast Cancer Diagnostics by a Au Nanoflare Probe | Q57795096 | ||
| Paclitaxel‑resistant gastric cancer MGC‑803 cells promote epithelial‑to‑mesenchymal transition and chemoresistance in paclitaxel‑sensitive cells via exosomal delivery of miR‑155‑5p | Q58581353 | ||
| Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges | Q26740577 | ||
| Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies | Q26750639 | ||
| Metabolic reprogramming: the emerging concept and associated therapeutic strategies | Q26786595 | ||
| Emerging role of microRNAs in lipid metabolism | Q26852591 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5 | Q28191103 | ||
| Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits | Q28237197 | ||
| Regulation of microRNA biogenesis | Q28243976 | ||
| Why do cancers have high aerobic glycolysis? | Q28290710 | ||
| Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes) | Q28301329 | ||
| Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes | Q28609355 | ||
| Cancer epigenetics: from mechanism to therapy | Q29614799 | ||
| Cancer drug resistance: an evolving paradigm | Q29616694 | ||
| Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells | Q29937967 | ||
| Identifying and targeting cancer stem cells in the treatment of gastric cancer | Q30238811 | ||
| Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells | Q33560646 | ||
| Circulating Tumor DNA as Biomarkers for Cancer Detection | Q33632125 | ||
| Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner | Q33713586 | ||
| Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells | Q33757055 | ||
| Circulating exosomal miR-125a-3p as a novel biomarker for early-stage colon cancer | Q33829967 | ||
| Increased drug resistance is associated with reduced glucose levels and an enhanced glycolysis phenotype. | Q33842748 | ||
| Mutations in BRCA2 and taxane resistance in prostate cancer | Q33870601 | ||
| The DNA damage response: implications for tumor responses to radiation and chemotherapy | Q34449481 | ||
| Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer | Q34614989 | ||
| Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. | Q34645569 | ||
| Inhibition of MDR1 gene expression and enhancing cellular uptake for effective colon cancer treatment using dual-surface-functionalized nanoparticles. | Q35119565 | ||
| Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis | Q35234332 | ||
| Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters. | Q36143777 | ||
| BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group | Q36145443 | ||
| Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma | Q36294432 | ||
| Mechanisms and insights into drug resistance in cancer | Q36682301 | ||
| Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. | Q36764656 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| Linking metabolic reprogramming to therapy resistance in cancer | Q39075073 | ||
| EMT, CSCs, and drug resistance: the mechanistic link and clinical implications | Q39233875 | ||
| Current knowledge on exosome biogenesis and release | Q39451543 | ||
| Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. | Q39860485 | ||
| Exosome-Mediated Intercellular Communication between Hepatitis C Virus-Infected Hepatocytes and Hepatic Stellate Cells | Q40375820 | ||
| Sequence requirements for micro RNA processing and function in human cells | Q40674291 | ||
| Exosomal miRNAs and miRNA dysregulation in cancer-associated fibroblasts | Q41557851 | ||
| Circulating exosomal microRNA-96 promotes cell proliferation, migration and drug resistance by targeting LMO7. | Q42109363 | ||
| Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes | Q42371249 | ||
| Exosome - miR-335 as a novel therapeutic strategy in hepatocellular carcinoma | Q46288051 | ||
| Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression | Q47094323 | ||
| Cell-to-cell communication: microRNAs as hormones | Q47113309 | ||
| Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. | Q47267048 | ||
| Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365. | Q47312309 | ||
| Increased T-helper 17 cell differentiation mediated by exosome-mediated microRNA-451 redistribution in gastric cancer infiltrated T cells. | Q47615858 | ||
| Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. | Q47911670 | ||
| Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition | Q47955211 | ||
| ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway | Q47969892 | ||
| TRAF6 regulates tumour metastasis through EMT and CSC phenotypes in head and neck squamous cell carcinoma. | Q48199906 | ||
| Exosome-mediated breast cancer chemoresistance via miR-155 transfer | Q48231556 | ||
| The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models | Q48450569 | ||
| Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer | Q49509990 | ||
| miR-155 in cancer drug resistance and as target for miRNA-based therapeutics | Q49544999 | ||
| Targeting EHMT2 reverses EGFR-TKI resistance in NSCLC by epigenetically regulating the PTEN/AKT signaling pathway | Q49646693 | ||
| Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer | Q49887989 | ||
| Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma | Q92028464 | ||
| Insights into gemcitabine resistance and the potential for therapeutic monitoring | Q92105514 | ||
| Glucosamine reverses drug resistance in MRP2 overexpressing ovarian cancer cells | Q92185129 | ||
| The emerging treatment landscape of targeted therapy in non-small-cell lung cancer | Q92221532 | ||
| On-chip anticancer drug screening - Recent progress in microfluidic platforms to address challenges in chemotherapy | Q92244134 | ||
| Cancer‑associated fibroblast‑derived exosomal miR‑382‑5p promotes the migration and invasion of oral squamous cell carcinoma | Q92307123 | ||
| Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer | Q92368899 | ||
| Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2 | Q92435676 | ||
| GLUT1-mediated effective anti-miRNA21 pompon for cancer therapy | Q92435781 | ||
| High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer | Q92451925 | ||
| Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer | Q92586310 | ||
| Exosome-transmitted miR-567 reverses trastuzumab resistance by inhibiting ATG5 in breast cancer | Q92859994 | ||
| RAB27B-activated secretion of stem-like tumor exosomes delivers the biomarker microRNA-146a-5p, which promotes tumorigenesis and associates with an immunosuppressive tumor microenvironment in colorectal cancer | Q93070002 | ||
| Exosomal transfer of miR-214 mediates gefitinib resistance in non-small cell lung cancer | Q93246821 | ||
| Therapy resistance mediated by cancer stem cells | Q93339813 | ||
| Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers | Q36958682 | ||
| Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor | Q36992455 | ||
| Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. | Q37151539 | ||
| Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis | Q37186425 | ||
| Euphorbia factor L2 induces apoptosis in A549 cells through the mitochondrial pathway | Q37587302 | ||
| MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression | Q37660590 | ||
| Lactate: a metabolic key player in cancer | Q37956296 | ||
| DNA damage repair and tolerance: a role in chemotherapeutic drug resistance | Q38101577 | ||
| The network of P-glycoprotein and microRNAs interactions | Q38152293 | ||
| Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer | Q38215087 | ||
| PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy | Q38361400 | ||
| Cancer biomarker detection: recent achievements and challenges | Q38367682 | ||
| The stress protein TP53INP1 plays a tumor suppressive role by regulating metabolic homeostasis. | Q38557368 | ||
| Intercellular Transfer of Cancer Drug Resistance Traits by Extracellular Vesicles | Q38598070 | ||
| Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade | Q38616109 | ||
| Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p | Q38661866 | ||
| Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. | Q38680034 | ||
| Myostatin inhibits osteoblastic differentiation by suppressing osteocyte-derived exosomal microRNA-218: A novel mechanism in muscle-bone communication | Q38705141 | ||
| Exosomes from Plasmodium-infected hosts inhibit tumor angiogenesis in a murine Lewis lung cancer model | Q38709057 | ||
| The role of glucuronidation in drug resistance | Q38710791 | ||
| Loss of exosomal miR-320a from cancer-associated fibroblasts contributes to HCC proliferation and metastasis | Q38712410 | ||
| Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK. | Q38718324 | ||
| Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma | Q38727171 | ||
| Mesenchymal Stem Cell-Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow | Q38749562 | ||
| Six Serum-Based miRNAs as Potential Diagnostic Biomarkers for Gastric Cancer | Q38809238 | ||
| High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. | Q38826826 | ||
| ABC transporters as mediators of drug resistance and contributors to cancer cell biology. | Q38834784 | ||
| Apaf1 inhibition promotes cell recovery from apoptosis. | Q38836005 | ||
| Hallmarks of cancer stem cell metabolism. | Q38842974 | ||
| Evolving Strategies for Therapeutically Targeting Cancer Stem Cells | Q38906691 | ||
| Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. | Q38941237 | ||
| Approaches for targeting cancer stem cells drug resistance | Q38971795 | ||
| miRNA Biogenesis: A Dynamic Pathway. | Q38993993 | ||
| Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal | Q39014053 | ||
| Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg/Th17 cell imbalance in epithelial ovarian cancer | Q58609589 | ||
| Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p | Q58709083 | ||
| Exosomal microRNAs as tumor markers in epithelial ovarian cancer | Q58776553 | ||
| Protocol for serum exosomal miRNAs analysis in prostate cancer patients treated with radiotherapy | Q58786265 | ||
| Downregulation of exosomal let-7a-5p in dust exposed- workers contributes to lung cancer development | Q59801930 | ||
| Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis | Q60300793 | ||
| Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer | Q60312777 | ||
| Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5 | Q61448904 | ||
| Translocator Protein (TSPO) as a Potential Biomarker in Human Cancers | Q61955104 | ||
| Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications | Q64062639 | ||
| Therapeutic Targeting of Cancer Stem Cells: Integrating and Exploiting the Acidic Niche | Q64075525 | ||
| Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer | Q64076951 | ||
| Targeting exon 20 insertion mutations in non-small cell lung cancer | Q64118764 | ||
| Multicomponent assemblies in DNA-double-strand break repair by NHEJ | Q64386858 | ||
| Regulation of DNA repair in the absence of classical non-homologous end joining | Q64389426 | ||
| Control of Invasion by Epithelial-to-Mesenchymal Transition Programs during Metastasis. | Q64880754 | ||
| Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas. | Q64991304 | ||
| Inhibitory effect of tumor cell-derived lactic acid on human T cells | Q79666516 | ||
| Exosomes Derived from Hypoxic Oral Squamous Cell Carcinoma Cells Deliver miR-21 to Normoxic Cells to Elicit a Prometastatic Phenotype | Q87491130 | ||
| Controlled drug delivery vehicles for cancer treatment and their performance | Q88114831 | ||
| Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells | Q88377569 | ||
| Circulating Exosomal miR-27a and miR-130a Act as Novel Diagnostic and Prognostic Biomarkers of Colorectal Cancer | Q88608096 | ||
| Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer | Q88635678 | ||
| Exosome-mediated miR-222 transferring: An insight into NF-κB-mediated breast cancer metastasis | Q88737471 | ||
| Emerging trends in biomarker discovery: Ease of prognosis and prediction in cancer | Q88950498 | ||
| Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis | Q89030115 | ||
| EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration | Q89151859 | ||
| A nanomedicine approach enables co-delivery of cyclosporin A and gefitinib to potentiate the therapeutic efficacy in drug-resistant lung cancer | Q89247069 | ||
| Identification of cisplatin sensitizers through high-throughput combinatorial screening | Q89341492 | ||
| High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer | Q89393391 | ||
| Exosomal miR-9 inhibits angiogenesis by targeting MDK and regulating PDK/AKT pathway in nasopharyngeal carcinoma | Q90003219 | ||
| Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma | Q90450945 | ||
| Exosomes in cancer therapy: a novel experimental strategy | Q90573148 | ||
| Exosome mediated multidrug resistance in cancer | Q90573157 | ||
| Lung cancer stem cells: origin, features, maintenance mechanisms and therapeutic targeting | Q90585676 | ||
| Exosomal miRNA-139 in cancer-associated fibroblasts inhibits gastric cancer progression by repressing MMP11 expression | Q90599300 | ||
| Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance | Q90721202 | ||
| Exosomal Transfer Of Cisplatin-Induced miR-425-3p Confers Cisplatin Resistance In NSCLC Through Activating Autophagy | Q90834908 | ||
| EGFR TKIs impair lysosome-dependent degradation of SQSTM1 to compromise the effectiveness in lung cancer | Q90862813 | ||
| Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer | Q90899949 | ||
| Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma | Q90918715 | ||
| Exosome-mediated miR-200b promotes colorectal cancer proliferation upon TGF-β1 exposure | Q91006681 | ||
| Loss of exosomal miR-148b from cancer-associated fibroblasts promotes endometrial cancer cell invasion and cancer metastasis | Q91148351 | ||
| Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210 | Q91237375 | ||
| Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer | Q91284256 | ||
| The roles of exosomal miRNAs and lncRNAs in lung diseases | Q91287758 | ||
| Novel exosomal miR-46146 transfer oxaliplatin chemoresistance in colorectal cancer | Q91289789 | ||
| Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis | Q91387285 | ||
| Stem cell fate in cancer growth, progression and therapy resistance | Q91518791 | ||
| Therapeutics strategies against cancer stem cell in breast cancer | Q91649682 | ||
| Role of p38γ MAPK in regulation of EMT and cancer stem cells | Q91716694 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 472 | |
| P577 | publication date | 2020-04-07 | |
| P1433 | published in | Frontiers in Oncology | Q26839986 |
| P1476 | title | The Role of Exosomal microRNA in Cancer Drug Resistance | |
| P478 | volume | 10 |
| Q100736946 | Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression |
| Q100534618 | Molecular and cellular paradigms of multidrug resistance in cancer |
Search more.